Efficiency and Safety of Brentuximab Vedotine as a Salvage Treatment Before Autologous Stem Cell Transplantation in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma: Retrospective Study

Documenti analoghi

• Outcome of malignant lymphoma in Ukraine. Analysis of 563 cases registered in the Ukrainian Lymphoma Registry in 2019–2021
  di: Yana Stepanishyna, et al.
  Pubblicazione: (2024)
• Post‐Engraftment Syndrome Following Autologous Haematopoietic Stem Cell Transplantation in a Patient With Relapsed Hodgkin Lymphoma
  di: Bader J. Alghamdi, et al.
  Pubblicazione: (2025)
• International Cost‐Effectiveness Analysis of Nivolumab Versus Brentuximab Vedotin for Patients With Advanced‐Stage Classic Hodgkin's Lymphoma
  di: Youwen Zhu, et al.
  Pubblicazione: (2026)
• Optimizing Brentuximab Vedotin Dosing in Pediatric Patients with Advanced Hodgkin Lymphoma: A Population Pharmacokinetic and Exposure‐Response Analysis
  di: Xiaofei Zhou, et al.
  Pubblicazione: (2025)
• Assessment of the Tolerability and Optimal Dosing of the Combination of Brentuximab Vedotin and Lenalidomide in Patients With Relapsed or Refractory T‐cell Lymphoma: Results of a Single‐centre Phase 1 Dose‐escalation Study
  di: Carrie van der Weyden, et al.
  Pubblicazione: (2025)